Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Irene A. Retmana"'
Autor:
Jamie Rijmers, Irene A. Retmana, Viët Bui, Davinia Arguedas, Maria C. Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116720- (2024)
Opnurasib (JDQ443) is a newly developed oral KRASG12C inhibitor, with a binding mechanism distinct from the registered KRASG12C inhibitors sotorasib and adagrasib. Phase I and II clinical trials for opnurasib in NSCLC are ongoing. We evaluated the ph
Externí odkaz:
https://doaj.org/article/aee126997e694d2fb3116e085d0ab755
Autor:
Nancy H.C. Loos, Irene A. Retmana, Jamie Rijmers, Yaogeng Wang, Changpei Gan, Maria C. Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115304- (2023)
Adagrasib (Krazati™) is the second FDA-approved specific KRASG12C inhibitor for non-small cell lung cancer (NSCLC) patients harboring this mutation. The impact of the drug efflux transporters ABCB1 and ABCG2, and the drug-metabolizing enzymes CYP3A
Externí odkaz:
https://doaj.org/article/d1dc8905ed1b43a4a3acf85b155c81d5
Autor:
Coen A.L. Stalpers, Irene A. Retmana, Jeroen L.A. Pennings, Rob J. Vandebriel, Coenraad F.M. Hendriksen, Arnoud M. Akkermans, Marcel H.N. Hoefnagel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613edb9d9e628d2f388d385268310025
http://hdl.handle.net/10029/625757
http://hdl.handle.net/10029/625757
Autor:
Nancy H C, Loos, Irene A, Retmana, Wenlong, Li, Margarida L F, Martins, Maria C, Lebre, Rolf W, Sparidans, Jos H, Beijnen, Alfred H, Schinkel
Publikováno v:
Pharmacological research. 178
Sotorasib (Lumakras™) is the first FDA-approved KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::231e9b6b4d3b68fe073f7045ff2ca8f8
https://pubmed.ncbi.nlm.nih.gov/35192958
https://pubmed.ncbi.nlm.nih.gov/35192958
Autor:
Arnoud M. Akkermans, Irene A. Retmana, Coenraad F.M. Hendriksen, Coen A.L. Stalpers, Marcel H.N. Hoefnagel, Jeroen L. A. Pennings, Rob J. Vandebriel
Publikováno v:
Vaccine
For batch release of legacy vaccines such as DTaP, in vivo potency release assays are required. We quantified the variability of in vivo potency release assays for four DTaP (Diphtheria, Tetanus, acellular Pertussis) products of different manufacture
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4125c32230f63ab7f7f64c6947ed338b